GGrantIndex
← Leaderboards

Timothy P Padera

Massachusetts General Hospital

$10,637,651
Attributed
$12,823,130
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.9M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,823,130 · 11

By mechanism

R01$7,825,253 · 4
DP2$2,613,250 · 1
R21$1,396,000 · 3
R00$698,507 · 1
K99$285,120 · 1
R13$5,000 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Prevent

Research focus

PreventResponseLymph NodesAnimal ModelImmune ResponseCellsLymphaticCancer CellPlayNeoplasm MetastasisLymphatic SystemMalignant NeoplasmsSignal TransductionMouse ModelTissuesIn VivoBiologyImmuneLymph FlowMolecularLymphatic VesselLaboratoriesPathway InteractionsAffect

Grant awards (30)

Targeting lymph node metastases to block cancer progression$499,258
R01 · FY2025 · CA · contact PI
Systems Biology of Antigen and T-Cell Transport in Cancer Immunotherapy$488,228
R01 · FY2025 · CA · contact PI
Targeting lymph node metastases to block cancer progression$474,295
R01 · FY2024 · CA · contact PI
Systems Biology of Antigen and T-Cell Transport in Cancer Immunotherapy$463,816
R01 · FY2024 · CA · contact PI
Systems Biology of Antigen and T-Cell Transport in Cancer Immunotherapy$504,978
R01 · FY2023 · CA · contact PI
Targeting lymph node metastases to block cancer progression$499,258
R01 · FY2023 · CA · contact PI
Reversing aging-induced lymphatic dysfunction to improve immune function$209,320
R21 · FY2023 · AG · contact PI
Reversing aging-induced lymphatic dysfunction to improve immune function$248,600
R21 · FY2022 · AG · contact PI
Targeting lymph node metastases to prevent cancer progression$69,448
R01 · FY2022 · CA · contact PI
2022 Lymphatics GRC and GRS$5,000
R13 · FY2022 · HL · contact PI
Targeting lymph node metastases to prevent cancer progression$381,448
R01 · FY2021 · CA · contact PI
Targeting lymph node metastases to prevent cancer progression$381,448
R01 · FY2020 · CA · contact PI
Systems biology of lymphatic transport$579,065
R01 · FY2019 · HL
Targeting lymph node metastases to prevent cancer progression$370,003
R01 · FY2019 · CA · contact PI
Mechanism of methicillin-resistant Staphylococcus aureus induced lymphatic dysfunction$209,255
R21 · FY2019 · AI · contact PI
Systems biology of lymphatic transport$579,389
R01 · FY2018 · HL
Targeting lymph node metastases to prevent cancer progression$384,094
R01 · FY2018 · CA · contact PI
Mechanism of methicillin-resistant Staphylococcus aureus induced lymphatic dysfunction$249,325
R21 · FY2018 · AI · contact PI
Systems biology of lymphatic transport$579,683
R01 · FY2017 · HL
Targeting lymph node metastases to prevent cancer progression$395,043
R01 · FY2017 · CA · contact PI
Systems biology of lymphatic transport$579,944
R01 · FY2016 · HL
Systems biology of lymphatic transport$595,855
R01 · FY2015 · HL
Lymphatic Radiobiology$219,444
R00 · FY2013 · CA · contact PI
Characterization of lymphatic contraction during infection$217,500
R21 · FY2013 · AI · contact PI
Characterization of lymphatic contraction during infection$262,000
R21 · FY2012 · AI · contact PI
Lymphatic Radiobiology$237,531
R00 · FY2012 · CA · contact PI
Characterizing lymphatic micrometastases: prognostic and therapeutic implications$2,613,250
DP2 · FY2011 · OD · contact PI
Lymphatic Radiobiology$241,532
R00 · FY2011 · CA · contact PI
Lymphatic Radiobiology$142,560
K99 · FY2009 · CA · contact PI
Lymphatic Radiobiology$142,560
K99 · FY2008 · CA · contact PI